卡维地洛防治肝硬化食管静脉曲张破裂出血的作用进展

牛晓卫; 刘同亭; 魏志

doi:10.3969/j.issn.1001-5256.2018.01.040

卡维地洛防治肝硬化食管静脉曲张破裂出血的作用进展

DOI: 10.3969/j.issn.1001-5256.2018.01.040

1. 山东中医药大学济南军区总医院研究生培训基地
2. 济南军区总医院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 4534
- HTML全文浏览量: 14
- PDF下载量: 414
- 被引次数: 0
出版历程
- 出版日期: 2018-01-20

Advances in the effect of carvedilol in prevention and treatment of esophageal variceal bleeding in patients with cirrhosis

Postgraduate Training Base, Jinan Military General Hospital, Shandong University of Traditional Chinese Medince, Jinan 250000, China

摘要

摘要:
卡维地洛作为新一代非选择性β受体阻断剂,其β受体阻滞作用已被证明是普萘洛尔的2~4倍,广泛应用于心力衰竭的有效治疗,然而其在降低肝门静脉压力、防治食管静脉曲张出血等方面是否发挥了同样的效用还存在争议。对比分析了卡维地洛与普萘洛尔、内镜下套扎在防治出血方面的临床应用研究,并总结了卡维地洛的药理作用、临床作用、应用剂量及不良反应,认为卡维地洛可显著改善门静脉高压的血流动力学紊乱,有望成为防治食管静脉曲张破裂出血的前沿药物。
- 肝硬化 /
- 食管和胃静脉曲张 /
- 卡维地洛 /
- 治疗 /
- 综述
Abstract:
Carvedilol is a new non-selective beta blocker, and studies have proven that the effect of carvedilol in receptor blocking is 2-4 times that of propranolol. Carvedilol is widely used in the treatment of heart failure. However, there are still controversies over its effect in reducing portal pressure and preventing esophageal variceal bleeding. This article analyzes and compares the clinical application of carvedilol, propranolol, and endoscopic variceal ligation in the prevention and treatment of bleeding and summarizes the pharmacological action, clinical effect, dose, and adverse reactions of carvedilol. It is pointed out that carvedilol can significantly improve hemodynamic disorder caused by portal hypertension and thus may become a new drug for the prevention and treatment of esophageal variceal bleeding.
- liver cirrhosis /
- esophageal and gastric varices /
- carvedilol /
- therapy /
- review

HTML全文

参考文献(37)

[1]BURZA MA, MARSCHALL HU, NAPOLEONE L, et al.The 35-year odyssey of beta blockers in cirrhosis:any gender difference in sight?[J].Pharmacol Res, 2017, 119:20-26.

[2]VOROBIOFF JD, GROSZMANN RJ.Prevention of portal hypertension:from variceal development to clinical decompensation[J].Hepatology, 2015, 61 (1) :375-381.

[3]BRU7) HA R, PETRTY'L J.Evaluation and treatment of portal hypertension[J].Cas Lek Cesk, 2016, 155 (2) :22-26.

[4]BRUNNER F, BERZIGOTTI A, BOSCH J.Prevention and treatment of variceal haemorrhage in 2017[J].Liver Int, 2017, 37 (Suppl 1) :104-115.

[5]NEUGEBAUER G, AKPAN W, von MOLLENDORFF E, et al.Pharmacokinetics and disposition of carvedilol in humans[J].J Cardiovasc Pharmacol, 1987, 10 (Suppl 11) :s85-s88.

[6]ALVES JM, PRADO LD, ROCHA HV.Evaluation and correlation of the physicochemical properties of carvedilol[J].Pharm Dev Technol, 2016, 21 (7) :856-866.

[7]HONDA M, OGURA Y, TOYODA W, et al.Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54healthy Japanese volunteers[J].Biol Pharm Bull, 2006, 29 (4) :772-778.

[8]TAKEKUMA Y, YAGISAWA K, SUGAWARA M.Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes[J].Biol Pharm Bull, 2012, 35 (2) :151-163.

[9]ASHKENAZI E, KOVALEV Y, ZUCKERMAN E.Evaluation and treatment of esophageal varices in the cirrhotic patient[J].Isr Med Assoc J, 2013, 15 (2) :109-115.

[10]GUPTA V, RAWAT R, SHALIMAR, et al.Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed:RCT[J].Hepatol Int, 2017, 11 (2) :181-187.

[11]ABID S, ALI S, BAIG MA, et al.Is it time to replace propranolol with carvedilol for portal hypertension?[J].World J Gastrointest Endosc, 2015, 7 (5) :532-539.

[12]SINAGRA E, PERRICONE G, D'AMICO M, et al.Systematic review with meta-analysis:the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J].Aliment Pharmacol Ther, 2014, 39 (6) :557-568.

[13]BHARDWAJ A, KEDARISETTY CK, VASHISHTHA C, et al.Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis:a randomised placebo-controlled trial[J].Gut, 2017, 66 (10) :1838-1843.

[14]WADHAWAN M, DUBEY S, SHARMA BC, et al.Hepatic venous pressure gradient in cirrhosis:correlation with the size of varices, bleeding, ascites, and child's status[J].Dig Dis Sci, 2006, 51 (12) :2264-2269.

[15]SARIN SK, MISHRA SR, SHARMA P, et al.Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis:a randomized controlled trial[J].Hepatol Int, 2013, 7 (1) :248-256.

[16]EL-DEMERDASH E, ABDEL-SATTAR SA, EL-BAKLY WM, et al.Antifibrotic effects of carvedilol and impact of liver fibrosis on carvedilol pharmacokinetics in a rat model[J].Eur J Drug Metab Pharmacokinet, 2017, 42 (5) :767-779.

[17]ARAU'JO JU'NIOR RF, GARCIA VB, LEITAO RF, et al.Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells[J].PLo S One, 2016, 11 (2) :e0148868.

[18]KAZEMI F, KETTANEH A, N'KONTCHOU G, et al.Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices[J].J Hepatol, 2006, 45 (2) :230-235.

[19]REIBERGER T, FERLITSCH A, PAYER BA, et al.Non-selectiveβ-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis[J].J Gastroenterol, 2012, 47 (5) :561-568.

[20]AUGUSTIN S, PONS M, MAURICE JB, et al.Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease[J].Hepatology, 2017.[Epub ahead of print]

[21]REIBERGER T, ULBRICH G, FERLITSCH A, et al.Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J].Gut, 2013, 62 (11) :1634-1641.

[22]KIM SG, KIM TY, SOHN JH, et al.A randomized, multi-center, open-label study to evaluate the efficacy of carvedilol vs.propranolol to reduce portal pressure in patients with liver cirrhosis[J].Am J Gastroenterol, 2016, 111 (11) :1582-1590.

[23]AGARWALA V, PRAKASH G, SINGH R, et al.Evaluation of treatment with carvedilol in comparison to propranolol in primary/secondary prophylaxis of gastroesophageal variceal bleeding[J].Indian J Gastroenterol, 2011, 30 (Suppl 1) :a46.

[24]BANRES R, MOITINHO E, MATILLA A, et al.Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J].Hepatology, 2002, 36 (6) :1367-1373.

[25]HOBOLTH L, MØLLER S, GRØNBÆK H, et al.Carvedilol or propranolol in portal hypertension?A randomized comparison[J].Scand J Gastroenterol, 2012, 47 (4) :467-474.

[26]LO GH.Did carvedilol really have more severe adverse events than propranolol in cirrhotic patients?[J].Am J Gastroenterol, 2017, 112 (5) :808.

[27]TRIPATHI D, FERGUSON JW, KOCHAR N, et al.Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed[J].Hepatology, 2009, 50 (3) :825-833.

[28]TRIANTOS C, VLACHOGIANNAKOS J, ARMONIS A, et al.Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers:a randomized trial of ligation[J].Aliment Pharmacol Ther, 2005, 21 (12) :1435-1443.

[29]SHRESTHA B, KC S, CHAUDHARY S, et al.Outcome of endoscopic variceal band ligation[J].JNMA J Nepal Med Assoc, 2017, 56 (206) :198-202.

[30]WANI ZA, BAHT RA, BHADORIA AS, et al.After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis?[J].Saudi J Gastroenterol, 2015, 21 (5) :278-283.

[31]RASOOL MF, KHALIL F, LAER S.Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based pharmacokinetic modeling approach[J].Eur J Drug Metab Pharmacokinet, 2017, 42 (3) :383-396.

[32]TRIPATHI D, STANLEY AJ, HAYES PC, et al.U.K.guidelines on the management of variceal haemorrhage in cirrhotic patients[J].Gut, 2015, 64 (11) :1680-1704.

[33]KIRNAKE V, ARORA A, GUPTA V, et al.Hemodynamic response to carvedilol is maintained for long periods and leads to better clinical outcome in cirrhosis:a prospective study[J].J Clin Exp Hepatol, 2016, 6 (3) :175-185.

[34]LAY CS, TSAI YT, LEE FY, et al.Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis[J].J Gastroenterol Hepatol, 2006, 21 (2) :413-419.

[35]ONALI S, KALAFATELI M, MAJUMDAR A, et al.Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites[J].Liver Int, 2017, 37 (9) :1334-1344.

[36]THORHAUGE KH, LINDVIG KP, LALEMAN W, et al.Lack of consensus for usage of beta-blockers in end-stage liver disease[J].Gut, 2016, 65 (6) :1058-1060.

[37]MANDORFER M, REIBERGER T.Beta blockers and cirrhosis, 2016[J].Dig Liver Dis, 2017, 49 (1) :3-10.

施引文献

资源附件(0)

访问统计